摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-chloro-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine | 28593-25-1

中文名称
——
中文别名
——
英文名称
8-chloro-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine
英文别名
8-Chlor-6-methyl-s-triazolo<4,3-b>pyridazin;8-Chloro-6-methyl[1,2,4]triazolo[4,3-b]pyridazine
8-chloro-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine化学式
CAS
28593-25-1
化学式
C6H5ClN4
mdl
MFCD00829394
分子量
168.585
InChiKey
DLYNIGWBDORRRL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
    申请人:江西科技师范大学
    公开号:CN110407839B
    公开(公告)日:2022-01-04
    本发明公开了一种含杂芳基酰胺结构的三唑并杂环类化合物、其几何异构体及其药学上可接受的盐、水合物、溶剂化物或前药。本发明含杂芳基酰胺结构的三唑并杂环类化合物,及其药学上可接受的盐、水合物或溶剂化物作为活性成份,与药学上可接受的载体或赋型剂混合制备成组合物,并制备成临床上可接受的剂型。本发明化合物具有强的抑制c‑Met激酶的作用,且对EGFR显示出较好的抑制活性,在制备治疗由于c‑Met、EGFR激酶异常高表达所引起疾病的药物中的应用,特别是在制备治疗和/或预防癌症的药物中的应用。
  • Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3-<i>b</i>]pyridazin-8-amine Derivatives as Tankyrase Inhibitors
    作者:Paride Liscio、Andrea Carotti、Stefania Asciutti、Tobias Karlberg、Daniele Bellocchi、Laura Llacuna、Antonio Macchiarulo、Stuart A Aaronson、Herwig Schüler、Roberto Pellicciari、Emidio Camaioni
    DOI:10.1021/jm401356t
    日期:2014.3.27
    Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.
  • Some s-Triazolo [b]pyridazines
    作者:Edgar A. Steck、R. Pauline Brundage
    DOI:10.1021/ja01532a043
    日期:1959.12
  • Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase
    作者:Alka Marwaha、John White、Farah El_Mazouni、Sharon A Creason、Sreekanth Kokkonda、Frederick S. Buckner、Susan A. Charman、Margaret A. Phillips、Pradipsinh K. Rathod
    DOI:10.1021/jm300351w
    日期:2012.9.13
    Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase that inhibit parasite in vitro growth with similar activity. Lead optimization of this series led to the recent identification of a preclinical candidate, showing good activity against P. falciparum in mice. As part of a backup program around this scaffold, we explored heteroatom rearrangement and substitution in the triazolopyrimidine ring and have identified several other ring configurations that are active as PfDHODH inhibitors. The imidazo[1,2-a]pyrimidines were shown to bind somewhat more potently than the triazolopyrimidines depending on the nature of the amino aniline substitution. DSM151, the best candidate in this series, binds with 4-fold better affinity (PfDHODH IC50 = 0.077 mu M) than the equivalent triazolopyrimidine and suppresses parasites in vivo in the Plasmodium berghei model.
  • 1,3-Dipolar Cycloadditions of Diazoalkanes to Heteroaromatic System. The Synthesis of Triazolo[4,3-b][1,2]diazepine and Cyclopropa[e]pyrazolo[4,3-c]azolo[1,5-a]pyridine Derivatives
    作者:Branko Stanovnik、Gorazd Habjan、Miha Tisler、Ljubo Golic、Ivan Leban
    DOI:10.3987/com-88-s9
    日期:——
查看更多

同类化合物

苯乙酰胺,4-[1-乙基-1-[4-(3-羟基-3,4,4-三甲代戊基)-3-甲基苯基]丙基]-a-羟基-2-甲基- 嗪多群 伯瑞替尼 [1-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基甲基]环己基]甲烷磺酰胺 [1,2,4]噻唑并[4,3-b]吡嗪-6-羧酸 [1,2,4]三唑并[4,3-b]哒嗪-8-甲酰胺 [1,2,4]三唑并[4,3-b]哒嗪-6-胺 [1,2,4]三唑并[4,3-b]哒嗪-3-羧酸 [1,2,4]三唑并[4,3-b]哒嗪-3-甲醛 [1,2,4]三唑并[4,3-b]哒嗪-3-甲酰胺 [1,2,4]三唑并[4,3-b]哒嗪-3,6-二胺 N,N-二甲基-3-([1,2,4]三唑并[1,5-b]哒嗪-6-氧基)丙烷-1-磺酰胺 7-氨基-6-甲基-[1,2,4]噻唑并-[4,3-b]吡嗪-8-醇 6H-嘌呤-6-硫酮,3-乙基-3,9-二氢- 6-肼基[1,2,4]噻唑并[4,3-b]吡嗪 6-肼基-3-甲基[1,2,4]三唑并[4,3-b]哒嗪 6-甲氧基-[1,2,4]三唑并[4,3-B]哒嗪 6-甲基-[1,2,4]噻唑并[4,3-b]吡嗪 6-甲基-[1,2,4]噻唑并[1,5-b]吡嗪 6-甲基-[1,2,4]三唑并[4,3-B]哒嗪-8-胺 6-氯[1,2,4]噻唑并[4,3-b]吡嗪-3-胺 6-氯[1,2,4]噻唑并[4,3-b]吡嗪-3-硫醇 6-氯[1,2,4]噻唑并[1,5-b]吡嗪 6-氯-[1,2,4]噻唑并[1,5-b]吡嗪-2-羧酸甲酯 6-氯-[1,2,4]三唑并[4,3-b]哒嗪-3-羧酸甲酯 6-氯-[1,2,4]三唑并[4,3-B]哒嗪-3-羧酸乙酯 6-氯-[1,2,4]三唑并[1,5-b]哒嗪-2-羧酸 6-氯-3-甲基[1,2,4]三唑并[4,3-B]哒嗪 6-氯-3-甲基-[1,2,4]三唑并[4,3-B]哒嗪-8-胺 6-氯-3-(三氟甲基)[1,2,4]噻唑并[4,3-b]吡嗪 6-氯-2-甲基-s-噻唑并[1,5-b]吡嗪 6-氯-2-(三氟甲基)-[1,2,4]噻唑并[1,5-b]吡嗪 6-氯-2-(1,1-二甲基乙基)-[1,2,4]三唑并[1,5-b]哒嗪 6-氯-1,2,4-三唑并[4,3-b]哒嗪 6-乙氧基-5H-[1,2,4]三唑并[4,3-b]哒嗪-8-酮 6-(三氟甲基)-[1,2,4]三唑并[4,3-B]哒嗪 6,8-二甲基-1,2,4-三唑并[4,3-B]哒嗪 5-乙基-5-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基甲基]庚烷-1-磺酰胺 5,5-二甲基-6-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基]己烷-1-磺酰胺 4,4-二甲基-5-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基]戊烷-1-磺酰胺 3-甲基-7-(2-苯基乙基)[1,2,4]三唑并[4,3-b]哒嗪 3-甲基-2-{[(7-甲基[1,2,4]三唑并[1,5-b]哒嗪-6-基)氧代]甲基}丁烷-1-磺酰胺 3-溴-[1,2,4]三唑并[4,3-B]哒嗪 3-氯-[1,2,4]三唑并[4,3-b]哒嗪 3-氯-6-甲基[1,2,4]三唑并[4,3-B]哒嗪 3-[(7,8-二甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基]-2,2-二甲基丙烷-1-磺酰胺 3,6-二氯并[1,2,4]噻唑并[4,3-b]哒嗪 2-甲基-2-丙基6-氯[1,2,4]三唑并[1,5-b]哒嗪-2-羧酸酯 2-甲基-2-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基甲基]丁烷-1-磺酰胺 2-[1-[(7-甲基-[1,2,4]三唑并[5,1-f]哒嗪-6-基)氧基甲基]环己基]乙烷磺酰胺